CRL Form 4: Interim CFO reports 2,926 RSUs at $170.88; total 13,460
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
Rhea-AI Filing Summary
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,926 | $170.88 | $500K |
Footnotes (1)
- F1. 50% of the unvested restricted stock units vest on November 6, 2026, with the remaining 50% vesting on November 6, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CRL’s Interim CFO report on Form 4?
What is the vesting schedule for the CRL RSUs?
Who is the reporting person for CRL?
What does transaction code A indicate in the CRL filing?
What company and ticker does the Form 4 relate to?
AI-generated analysis. How Rhea-AI works. Not financial advice.